AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA SurpriseSeeking Alpha • 02/04/26
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)Seeking Alpha • 02/04/26
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/04/26
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugsReuters • 02/04/26
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial ProgramPRNewsWire • 02/03/26
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With VitiligoPRNewsWire • 02/03/26
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 01/30/26